← Eichor
Study identifier: NCT06501183 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Condition: CDH17-positive Advanced Malignant Solid Tumors  ·  Sponsor: Shanghai Pudong Hospital

PhasePhase 1
Planned participants17
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Zhiguo Long  ·  18117253161  ·  zglong1976@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Pudong hospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06501183